Used primarily in the treatment of myelofibrosis, a rare bone marrow disorder, fedratinib is a kinase inhibitor that targets the FMS-like tyrosine kinase 3 (FLT3) and Janus kinase 2 (JAK2). It helps reduce spleen size and alleviate symptoms such as fatigue, night sweats, and abdominal discomfort in patients with intermediate-2 or high-risk myelofibrosis. The drug is especially considered for patients who have not responded to or cannot tolerate other JAK inhibitors. Its mechanism involves blocking signaling pathways involved in the proliferation of abnormal hematopoietic cells, thereby helping control disease progression. Fedratinib is taken orally and has shown clinical benefit in improving quality of life and disease-related symptoms. However, due to potential side effects like serious encephalopathy, including Wernicke's encephalopathy, careful patient monitoring is required during treatment.